Browsing Tag
NASDAQ
348 posts
Viatris and the presbyopia drug race: What ASCRS 2026 data means for the MR-141 FDA decision in October
Viatris presents full VEGA-3 Phase 3 data for MR-141 presbyopia drop at ASCRS 2026. FDA PDUFA date is October 17, 2026. Market context, competitive landscape, and investor outlook.
Why Terra Quantum is heading to Wall Street now and what MLAA investors are really buying
Terra Quantum AG plans a $3.25 billion SPAC deal with MLAC II. Read what it means for quantum commercialization, valuation risk, and MLAA stock.
CoreWeave lands Anthropic after Meta expansion, and suddenly the AI cloud race looks tighter
CoreWeave has signed Anthropic to a multi-year AI cloud deal. Read why the agreement matters for CRWV, competitors, debt risk, and AI infrastructure strategy.
Why Seaport’s U.S. IPO filing matters now for neuropsychiatric drug development and biotech capital markets
Seaport Therapeutics has filed for a U.S. IPO. Read how its neuropsychiatry pipeline could test biotech investor appetite in 2026.
SunOpta’s Refresco sale is closer now, but the real closing risk has not fully disappeared
SunOpta has cleared a major antitrust hurdle in its Refresco buyout. Read what the approval changes, what risks remain, and what it means for STKL.
DocuSign stock and IAM platform: What DOCU retail investors need to know in 2026
DocuSign reported $3.2B in fiscal 2026 revenue with IAM platform growth accelerating. Here is what investors and enterprise buyers need to know now.
Trident Digital Tech Holdings (NASDAQ: TDTH) targets Ghana MSMEs with RLUSD settlement and tax reporting model
Why Trident Digital Tech Holdings is using RLUSD in Ghana, what it could change for payments, and where the execution risks sit. Read more.
Why Glencore plc’s (LSE: GLEN) South Carolina recycling deal matters more than a routine minority stake
Glencore plc has bought a 45% stake in a South Carolina aluminum recycling plant. Read why this matters for United States supply chains and GLEN stock.
Why is Avalyn Pharma going public now, and what does it reveal about biotech risk appetite?
Avalyn Pharma has filed for a U.S. IPO to fund inhaled pulmonary fibrosis drugs. Read what the move signals for biotech markets and lung disease therapy.
Suja Life files for Nasdaq IPO as better-for-you beverage growth meets public market scrutiny
Suja Life has filed for a Nasdaq IPO. Read why its growth, debt load, brand mix, and category timing matter more than the filing itself.